Search research articles
Contact Us
Filters
Showing results (501-510 of 522) with videos related to
Page
of 53
Sort By:
Blood Cancer Journal
|
April 22, 2017
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
M A Dimopoulos, A K Stewart, T Masszi, et al.
Journal of Internal Medicine
|
February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
S Bringhen, A Milan, M D'Agostino, et al.
Leukemia Research
|
January 1, 1997
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study
J Thaler, W Hilbe, U Apfelbeck, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Leukemia
|
November 2, 2013
International Myeloma Working Group recommendations for global myeloma care
H Ludwig, J S Miguel, M A Dimopoulos, et al.
Nature Genetics
|
December 3, 2003
Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis
George Papanikolaou, Mark E Samuels, Erwin H Ludwig, et al.
Leukemia
|
April 23, 2010
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R A Kyle, B G M Durie, S V Rajkumar, et al.
Leukemia
|
July 21, 2006
International uniform response criteria for multiple myeloma
B G M Durie, J-L Harousseau, J S Miguel, et al.
Leukemia
|
July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R Hájek, T Masszi, M T Petrucci, et al.
Page
of 53
Search research articles
Search
Showing results (501-510 of 522) with videos related to
Sort By:
Page
of 53
Blood Cancer Journal
|
April 22, 2017
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
M A Dimopoulos, A K Stewart, T Masszi, et al.
Journal of Internal Medicine
|
February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
S Bringhen, A Milan, M D'Agostino, et al.
Leukemia Research
|
January 1, 1997
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study
J Thaler, W Hilbe, U Apfelbeck, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Leukemia
|
November 2, 2013
International Myeloma Working Group recommendations for global myeloma care
H Ludwig, J S Miguel, M A Dimopoulos, et al.
Nature Genetics
|
December 3, 2003
Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis
George Papanikolaou, Mark E Samuels, Erwin H Ludwig, et al.
Leukemia
|
April 23, 2010
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R A Kyle, B G M Durie, S V Rajkumar, et al.
Leukemia
|
July 21, 2006
International uniform response criteria for multiple myeloma
B G M Durie, J-L Harousseau, J S Miguel, et al.
Leukemia
|
July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R Hájek, T Masszi, M T Petrucci, et al.
Page
of 53